AllSci News
OneCyte and Kemp Proteins partner on integrated cell line development for biologics
OneCyte and Kemp Proteins announced a strategic partnership on April 3, 2026, combining their respective platform technologies to deliver integrated cell line…
Amgen's subcutaneous Tepezza meets primary endpoint in Phase III thyroid eye disease trial
Amgen (NASDAQ: AMGN) reported that a Phase III trial of subcutaneous teprotumumab-trbw (Tepezza) delivered via an on-body injector met its primary endpoint...
Quantum Bio filed IND for Lucid-MS to start Phase II in multiple sclerosis
Quantum BioPharma submitted an IND application to the U.S. Food and Drug Administration in March 2026 for Lucid-21-302, known as Lucid-MS, a small-molecule...
Opus Genetics secures USD 155m non-dilutive financing from Oberland Capital Management
Opus Genetics (NASDAQ: IRD), a clinical-stage gene therapy company focused on inherited retinal diseases and headquartered in Research Triangle Park, North...
Neurocrine expands rare disease portfolio via USD 2.9b acquisition of Soleno Therapeutics
Neurocrine Biosciences Expands Rare Disease Portfolio via USD 2.9 Billion Acquisition of Soleno Therapeutics
Stipple Bio closes USD 100m Series A financing for ADC pipeline
Cambridge, Massachusetts-based Stipple Bio, Inc., a private biotechnology company developing epitope-targeted cancer therapies, has closed a USD 100 million...
Pegasus Biotech and VIDO collaborate to advance plasma DNA platform
Canada-based Contract Research Organization (CRO) Pegasus Biotech Inc., announced a strategic collaboration with the Vaccine and Infectious Disease Organization (VIDO) at the…
FDA accepts Ultragenyx's UX111 gene therapy resubmission for Sanfilippo syndrome Type A treatment
Ultragenyx Pharmaceutical has submitted a resubmitted Biologics License Application to the US FDA for UX111 (rebisufligene etisparvovec), an AAV9 gene...
Immunome's 177Lu-IM-3050 enters Phase I trial targeting fibroblast activation protein-alpha
Immunome, Inc. has registered a first-in-human Phase 1 clinical trial for 177Lu-IM-3050, a lutetium-177-labeled radioligand targeting fibroblast activation...
Sunho Biologics' long-acting FGF21 fusion protein enters Phase I in China for hypertriglyceridemia
Sunho Biologics has registered a first-in-human Phase 1 clinical trial for ISH0688, a recombinant human IgG1 Fc-FGF21 fusion protein targeting...
Ferring pulls development of LHCGR-targeted fertility drug
Ferring Pharmaceuticals has terminated the Phase I Celestial-1 trial (NCT06466486), a study evaluating FE 999302 (choriogonadotropin beta, a recombinant...
Data committee gives nod for Vedanta's VE303 to advance in Phase III for C. difficile infection prevention
Vedanta Biosciences reported that an independent data monitoring committee has recommended the Phase III RESTORATiVE303 trial of VE303 continue without...
Alphamab's anbenitamab meets primary endpoint in Phase III HER2-positive breast cancer trial
Alphamab Oncology (HKEX: 9966) announced on March 31 that anbenitamab (KN026), a bispecific anti-HER2 antibody, met its primary endpoint in the Phase III...
China's Syneron Bio closes USD 150m Series B for Synova macrocyclic peptide platform
Beijing-based Syneron Bio has closed a USD 150 million Series B financing round to advance its macrocyclic peptide drug discovery platform and accelerate...
Immedica's lurbinectedin-atezolizumab combination gets CHMP nod for ES-SCLC maintenance
Lurbinectedin (Zepzelca) combined with atezolizumab has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products...
The AllSci Brief
Systematic R&D and deal news. Daily.